Print Page     Close Window     

SEC Filings

AC IMMUNE SA filed this Form 6-K on 06/28/2017
Entire Document

© 2017 AC Immune. Not to be used or reproduced without permission. Annual General Meeting | Lausanne | June 28, 2017 3 Highlights and achievements 2016/2017 Company ▪ Entered research collaboration agreement with Essex Bio - Technology for development of novel biological therapeutic for the treatment of neurodegenerative diseases and neuroinflammation ▪ Achieved milestone with Piramal Imaging for initiation of Phase 1 clinical trial in an orphan indication, Progressive Supranuclear Palsy ( PSP) ▪ Increased staff by more than 25% over 12 months with strong focus on Finance and R&D ( neuroinflammation and neuro - orphan ) ▪ Appointed Mr. Joerg Hornstein as Chief Financial Officer ▪ Secured net proceeds of $ 70.5 million (CHF 69.4 million) from Initial Public Offering at NASDAQ ▪ Received CHF 14 million milestone payment from Genentech for start of Phase 1 of anti - Tau antibody ▪ Secured CHF 42.7 million Series E crossover financing round from group of highly regarded investors ▪ Signed R&D collaboration agreement with Biogen focused on development of PET - ligands for α - synuclein and TDP - 43


© AC Immune 2015